CATX Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (CATX) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.26 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.0% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.